Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
REFERENCES Burris HA 3rd, Rugo HS, Vukelja SJ, et al, “Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy,” J Clin Oncol , 2011, 29(4):398-405. [PubMed 21172893 ] Hurvitz SA, Dirix L, Kocsis J, et al, “Phase II Randomized Study of Trastuzumab Emtansine versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer,” J Clin Oncol , 2013, 31(9):1157-63. [PubMed 23382472 ] Girish S, Gupta M, Wang B, et al, “Clinical Pharmacology of Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate in Development for the Treatment of HER2-Positive Cancer,” Cancer Chemother Pharmacol , 2012, 69(5):1229-40. [PubMed 22271209 ] Krop IE, LoRusso P, Miller KD, et al, “A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, aTaxane, and Capecitabine,” J Clin Oncol , 2012, 30(26):3234-41. [PubMed 22649126 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Verma S, Miles D, Gianni L, et al, “Trastuzumab Emtansine for HER2-positive Advanced Breast Cancer,” N Engl J Med , 2012, 367(19):1783-91. [PubMed 23020162 ] Topic 88427 Version 6.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]